Life Sciences Research Partners V.Z.W.

What Life Sciences Research Partners V.Z.W. does

Life Sciences Research Partners V.Z.W. (LSRP) is a Belgian non-profit scientific organization (Vereniging Zonder Winstoogmerk), headquartered at Campus Gasthuisberg, Herestraat 49, box 913, 3000 Leuven. The entity was established on July 2, 1988 as the D. Collen Research Foundation by D\u00e9sir\u00e9 Collen to channel income from the t-PA patent (US Patent No. 4,752,603, awarded June 21, 1988, co-invented by Collen, Rijken and Matsuo with Leuven Research and Development) into scientific research; because Belgian non-profit legislation in 2005 prohibited use of the terms 'foundation' and 'trust', it was renamed Life Sciences Research Partners on August 28, 2007 with bylaws published in the Belgian Official Gazette on September 19, 2007. LSRP is acknowledged by the Belgian Federal Government (via BELSPO) as a scientific institution and currently operates with 1\u201310 staff while supporting a research ecosystem that includes 40+ full-time collaborators at the Center for Molecular and Vascular Biology (CMVB) and more than 250 international alumni, plus affiliated foundations (D\u00e9sir\u00e9 Collen Stichting, FEFP), biotech participations (CoBioRes), and infrastructure (Bio-Incubator at Science Park Arenberg).

LSRP's core offering is research funding and research infrastructure rather than a commercial product. It provides research grants, research mandates, traveling scholarships, financial support of publications, and the organization of scientific congresses and symposia across thrombosis, hemostasis, platelet biology, fibrinolysis and cardiovascular health. It also operates a technology transfer and valorization service \u2014 mandated by KU Leuven to act as the bookkeeper and beneficiary-manager for funds generated by CMVB and the Vesalius Research Center (now Center for Cancer Biology) of VIB/KU Leuven \u2014 and runs dedicated facilities including the Marc Verstraete Fund (2018) for young researchers and the D\u00e9sir\u00e9 Collen Learning Center (~250 students) at Gasthuisberg. Beyond biomedical science it supports social-responsibility projects outside Belgium (Fundaci\u00f3n Tejedores de Sue\u00f1os in Costa Rica; Cocoa for Schools in Tanzania's 141 cocoa villages) and raises supplementary funds via benefit concerts (most recently scheduled for October 24, 2025 and February 24, 2026).

The business model is that of a finite-endowment non-profit. LSRP is primarily financed by the direct and indirect yields of KU Leuven's t-PA patent, which between 1987 and 2005 generated approximately $144 million in royalties from Genentech Inc.'s worldwide recombinant t-PA sales; the underlying US patent has since lapsed. LSRP has no public pricing model and reports a balance sheet total of €11,858,172 with a €7,731,792 cash position and a €570,370 net profit at end of fiscal year 2024, against a balance-sheet peak of €26.48 million in 2017. The single 'customer segment' is the academic and scientific research community (horizontal segmentation), with distributed grants and research mandates rather than contracted enterprise customers, and there are no reported named customers, ARR or GTM channels; the entity functions as a science-philanthropy platform rather than a commercial enterprise.

Name

Life Sciences Research Partners V.Z.W.

Legal name

Life Sciences Research Partners V.Z.W.

Website

https://lsrp.be

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Life Sciences Research Partners V.Z.W. (LSRP) is a Belgian non-profit scientific organization, established in 1988, that supports biomedical and biotechnological research at KU Leuven's CMVB, financed historically by t-PA patent royalties and now active through research grants, technology transfer management, the Bio-Incubator at Science Park Arenberg and affiliated biotech and foundation vehicles.

Ownership category

akta.pro rank

Product category

Biomedical Research Funding

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Patent Owners & Lessors (6794)

akta.pro primary industry

Research Administration & Grants Management Support (Pre/Post-Award, Compliance) (EDAEALAO)

Keywords

• Biomedical research funding
• Scientific research grants
• Biotechnology incubation
• Nonprofit research support
• Cardiovascular research financing

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Operations, Infrastructure, Marketing or Sales

Revenue model

1. t-PA Patent Royalties: LSRP is financed by the direct and indirect yields of KU Leuven's t-PA patent. Between 1987 and 2005, approximately $144 million in royalties were paid from the t-PA patent licensed to Genentech Inc. for worldwide sales of recombinant t-PA as a thrombolytic therapy for heart attacks.

Core offering

Life Sciences Research Partners (LSRP) is a Belgian non-profit organization that promotes, supports, and carries out scientific research with a special focus on biomedical and biotechnological projects. It channels t-PA patent royalty income into research grants, traveling scholarships, scientific congresses, publications, and young investigator support. LSRP also manages technology transfer and valorization for KU Leuven laboratories (CMVB and Vesalius Research Center) and holds participations in biotech ventures including the Bio-Incubator and CoBioRes.

Product overview

Life Sciences Research Partners (LSRP) is a non-profit organization that evolved in 2007 from the D. Collen Research Foundation. It operates as a platform for advancing biomedical sciences through multiple initiatives: the Marc Verstraete Fund provides grants to young researchers; technology transfer management services support KU Leuven laboratories; and participations in biotech ventures like CoBioRes and the Bio-Incubator facility. The organization also supports educational projects (Désiré Collen Learning Center) and community initiatives (Cocoa for Schools, Fundación Tejedores de Sueños), while organizing benefit concerts for fundraising. All activities are financed by t-PA patent royalties.

Differentiator

Problem solved

Functional benefit

Products and services

• Marc Verstraete Fund Grant program that provides research support to young researchers at the start of their career, honoring Prof. Marc Verstraete's pioneering contributions.
• Bio-Incubator Fully equipped lab and office space located in Science Park Arenberg in Leuven, offering tailor-made spaces ranging from 50 m2 to 500 m2 for young and innovative biotech companies.
• Technology Transfer and Valorization Management Service mandated by KU Leuven to manage technology transfer and valorization of the Center for Molecular and Vascular Biology (CMVB) and the Vesalius Research Center of VIB/KU Leuven, acting as bookkeeper for beneficiaries of generated funds.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and minor.

• Center for Molecular and Vascular Biology (CMVB)coreStrategic or Co-development PartnerCMVB was founded in 1947 by Prof. Dr. Marc Verstraete as a laboratory for blood coagulation. Located on Campus Gasthuisberg, it significantly contributed to the international recognition of KU Leuven. LSRP manages technology transfer and valorization for CMVB. Research covers thrombosis, hemostasis, platelet biology, fibrinolysis, and heart disease, culminating in the 1979 development of t-PA.
• Vlaams Instituut voor Biotechnologie (VIB) / Flanders Institute for BiotechnologycoreStrategic or Co-development PartnerIn 1995, a new department of VIB was established alongside the CMVB, named Center for Transgene Technology and Gene Therapy. The VIB lab was successively directed by Désiré Collen, Peter Carmeliet and presently Diether Lambrechts. It has moved to a new building (O&N4) and was renamed first as Vesalius Research Center and now as Center for Cancer Biology.
• FEFP (Foundation for Education to Improve Family Planning)minorOthersFEFP was founded in February 2020 by Désiré Collen and Chris Buyse as a Charitable Incorporated Organization (CIO) based in the United Kingdom. Chris Buyse is Managing Director since October 2022. FEFP supports international projects including Cocoa for Schools Tanzania and Fundación Tejedores de Sueños Costa Rica.
• CoBioResminorStrategic or Co-development PartnerCoBioRes is a Belgian biotech company founded in 2013 by Désiré Collen and located in Leuven. It focuses on development of targeted chemotherapies based on proprietary tetrapeptide-prodrug technology invented by Professor André Trouet of Université Catholique de Louvain.
• Bio-IncubatorcoreStrategic or Co-development PartnerThe Bio-Incubator, located in Science Park Arenberg in Leuven, offers fully equipped lab and office space to young and innovative biotech companies (50 m2 to 500 m2). LSRP has contributed financially to the construction and development. It is building its fourth unit to strengthen the life sciences ecosystem in the Leuven area.
• Désiré Collen Stichting / Désiré Collen Foundation (DCS/DCF)coreOthersDCS/DCF is a private foundation according to Belgian law, founded in 2015. It promotes economically and socially innovative projects and supports biomedical research, primarily in Belgium. It contributes to the Francqui Foundation (Belgium) and Fondation Louis Jeantet de Médecine (Switzerland).
• Fundación Tejedores de Sueños (Dreamweavers Foundation)minorOthersFounded in Costa Rica in 2010 by Linda de Donder. Provides access to secondary school education for Costa Rican youngsters through scholarships, school supplies, and uniforms. LSRP supports this project along with FEFP.
• Cocoa for SchoolsminorOthersSocial responsibility project by Kim's Chocolates NV focusing on community development in 141 cocoa growing villages in Tanzania's Southern Highlands. LSRP supported building a 4-classroom building in Mbugani (15 classrooms, 1300+ pupils, 32 teachers) and funding for a girls' boarding school.

Scale indicators4 records

Recent moves10 records

Expansion highlights4 records

Regional players

• ThromboGenics NV (now Oxurion): Belgian biotech originally founded by Désiré Collen (formerly CEO/Chairman) and spun out of the same CMVB/t-PA ecosystem. Comparable as a Leuven-based life sciences company sharing scientific lineage and ecosystem with LSRP, though operating as a commercial drug developer rather than a foundation.

Direct peers

• Fund+: Belgian life sciences investment firm founded and chaired by Désiré Collen with the D. Collen Stichting as a significant minority shareholder. Fund+ is directly comparable through its overlapping leadership, Belgian base, and life sciences investment mandate.
• Francqui Foundation: Belgian foundation supporting biomedical research through awards, chairs, and grants. LSRP explicitly contributes to the Francqui Foundation, and it operates with a similar Belgian scientific institution mandate targeting biomedical researchers.
• Fondation Louis Jeantet de Médecine: Swiss biomedical research foundation funding European medical researchers. LSRP explicitly contributes to it, and both organizations function as private non-profit foundations channeling resources into biomedical science with comparable governance and grant-making models.
• Research Foundation Flanders (FWO): Belgian Flemish research funding body that supports fundamental and applied scientific research through grants and mandates. Directly comparable to LSRP as a publicly-recognized research administration and grants management organization operating in the same Belgian life sciences ecosystem.

Broad incumbents

• Howard Hughes Medical Institute: Large US biomedical research foundation supporting investigator-driven science. Comparable to LSRP as a private, philanthropy-funded foundation channeling resources into biomedical research with a focus on enabling investigator productivity rather than running commercial operations.
• Novo Nordisk Foundation: Danish enterprise foundation supporting diabetes, biomedical research, and life sciences. Comparable to LSRP as a larger European foundation with a similar philanthropic funding model for biomedical and life sciences research.
• Wellcome Trust: Global charitable foundation focused on health and biomedical research funding. Comparable to LSRP as a much larger endowment-funded research foundation whose mission is to advance biomedical science through grants and institutional support rather than commercial activity.
• VIB (Flanders Institute for Biotechnology): Major Flemish life sciences research institute with which LSRP has a core strategic partnership (Center for Transgene Technology and Gene Therapy was established alongside CMVB). VIB is comparable as a larger institutional player in the same Belgian life sciences research ecosystem that LSRP supports.

Others

• BELSPO (Belgian Science Policy Office): Belgian Federal Science Policy Office, which is the body that officially recognizes LSRP as a scientific institution. Comparable as a federal Belgian entity that funds and coordinates scientific research, including biomedical research, providing a relevant adjacent reference point.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Sciences Research Partners V.Z.W.